Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Baxter
Merck
Dow
Mallinckrodt

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,695,122

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,695,122 protect, and when does it expire?

Patent 9,695,122 protects AVYCAZ and is included in one NDA.

This patent has twenty-five patent family members in seventeen countries.

Summary for Patent: 9,695,122
Title:Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Abstract: The present invention relates to compounds and processes for preparing compounds of Formula (I), ##STR00001## including compounds such as trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof (e.g., NXL-104).
Inventor(s): Ronsheim; Melanie Simone (Port Jefferson, NY), Racha; Saibaba (Smithtown, NY), Lawton; Graham Richard (Smithtown, NY), Zhou; Shao Hong (Commack, NY), Kalyan; Yuriy B. (Staten Island, NY), Golden; Michael (Macclesfield, GB), Milne; David (Macclesfield, GB), Telford; Alexander (Macclesfield, GB), Cherryman; Janette (Macclesfield, GB), Boyd; Alistair (Macclesfield, GB), Phillips; Andrew (Macclesfield, GB), Dedhiya; Mahendra G. (Pomona, NY)
Assignee: Forest Laboratories Holdings Ltd. (Hamilton, BM)
Application Number:15/040,654
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,695,122

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc AVYCAZ avibactam sodium; ceftazidime POWDER;IV (INFUSION) 206494-001 Feb 25, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Dow
Mallinckrodt
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.